Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

133 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomised, double-blind trial comparing budesonide formulations and dosages for short-term treatment of eosinophilic oesophagitis.
Miehlke S, Hruz P, Vieth M, Bussmann C, von Arnim U, Bajbouj M, Schlag C, Madisch A, Fibbe C, Wittenburg H, Allescher HD, Reinshagen M, Schubert S, Tack J, Müller M, Krummenerl P, Arts J, Mueller R, Dilger K, Greinwald R, Straumann A. Miehlke S, et al. Among authors: reinshagen m. Gut. 2016 Mar;65(3):390-9. doi: 10.1136/gutjnl-2014-308815. Epub 2015 Mar 19. Gut. 2016. PMID: 25792708 Free PMC article. Clinical Trial.
Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis.
Straumann A, Lucendo AJ, Miehlke S, Vieth M, Schlag C, Biedermann L, Vaquero CS, Ciriza de Los Rios C, Schmoecker C, Madisch A, Hruz P, Hayat J, von Arnim U, Bredenoord AJ, Schubert S, Mueller R, Greinwald R, Schoepfer A, Attwood S; International EOS-2 Study Group. Straumann A, et al. Gastroenterology. 2020 Nov;159(5):1672-1685.e5. doi: 10.1053/j.gastro.2020.07.039. Epub 2020 Jul 25. Gastroenterology. 2020. PMID: 32721437 Free article. Clinical Trial.
Thioguanine-nucleotides do not predict efficacy of tioguanine in Crohn's disease.
Herrlinger KR, Fellermann K, Fischer C, Kreisel W, Deibert P, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Greinwald R, Stange EF, Schwab M. Herrlinger KR, et al. Among authors: reinshagen m. Aliment Pharmacol Ther. 2004 Jun 15;19(12):1269-76. doi: 10.1111/j.1365-2036.2004.01947.x. Aliment Pharmacol Ther. 2004. PMID: 15191508 Free article.
6-thioguanine--efficacy and safety in chronic active Crohn's disease.
Herrlinger KR, Kreisel W, Schwab M, Schoelmerich J, Fleig WE, Ruhl A, Reinshagen M, Deibert P, Fellermann K, Greinwald R, Stange EF. Herrlinger KR, et al. Among authors: reinshagen m. Aliment Pharmacol Ther. 2003 Feb 15;17(4):503-8. doi: 10.1046/j.1365-2036.2003.01440.x. Aliment Pharmacol Ther. 2003. PMID: 12622758 Free article.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Danese S, Colombel JF, Lukas M, Gisbert JP, D'Haens G, Hayee B, Panaccione R, Kim HS, Reinisch W, Tyrrell H, Oh YS, Tole S, Chai A, Chamberlain-James K, Tang MT, Schreiber S; GARDENIA Study Group. Danese S, et al. Lancet Gastroenterol Hepatol. 2022 Feb;7(2):118-127. doi: 10.1016/S2468-1253(21)00294-6. Epub 2021 Nov 17. Lancet Gastroenterol Hepatol. 2022. PMID: 34798038 Free article. Clinical Trial.
133 results